ASCML
SRPT icon

ADKINS SEALE CAPITAL MANAGEMENT LLC’s Sarepta Therapeutics SRPT Stock Holding History

ADKINS SEALE CAPITAL MANAGEMENT LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$1.08K – 229
2025
Q4 		$1.08K Buy
+50
New +$1.05K ﹤0.01% 220

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADKINS SEALE CAPITAL MANAGEMENT LLC's SRPT Position: Q1 2026 in Review

ADKINS SEALE CAPITAL MANAGEMENT LLC sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 50 shares — an estimated $1.08K sold.

ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in SRPT in Q4 2025 and held it in 1 quarter. The position peaked at $1.08K in Q4 2025. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • ADKINS SEALE CAPITAL MANAGEMENT LLC reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC sold 50 Sarepta Therapeutics shares in Q1 2026, an estimated $1.08K.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 1 quarter.
  • ADKINS SEALE CAPITAL MANAGEMENT LLC's Sarepta Therapeutics position peaked at $1.08K in Q4 2025.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on ADKINS SEALE CAPITAL MANAGEMENT LLC's 13F filing for Q1 2026, filed 5 Aug 2026.